Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Medical products maker Cardinal Health Inc. would be allowed to resume production of pumps to control intravenous medication after fixing a problem that could have caused overdoses in the past, under a settlement with federal regulators the company announced Tuesday.

Over the last 12 years, there were 15 cases in which hospital patients could have received an overdose because of a sensitive keypad that programs how much medication the Alaris SE pump is to administer, Cardinal spokesman Troy Kirkpatrick said. Of the 15 cases, there were two injuries when the keypad recorded too much medicine.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 1 article* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.